Logo

Xbrane Reports Patient Enrollment Completion in P-lll XPLORE Study of Xlucane (biosimilar- ranibizumab)

Share this

Xbrane Reports Patient Enrollment Completion in P-lll XPLORE Study of Xlucane (biosimilar- ranibizumab)

Shots:

  • Xbrane reported that the last patient has been enrolled into the P-III XPLORE study assessing Xlucane vs Lucentis in 580 patients with wet AMD
  • The company will conduct an interim read-out from the XPLORE study when the last patient has reached 6mos. of their treatment schedule. Top-line data is expected to be communicated mid-2021 and filing of the MAA/BLA to EMA and the US FDA anticipated to take place imminently
  • Filing of MAA/BLA is expected to take place mid-2021. With an expected 12mos. regulatory process upon filing- MAA is expected in the EU and the US mid-2022 allowing for the launch of Xlucane

Click Here ­ Ref: XBrane | Image: XBrane

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions